| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,130 | 0,141 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 22.09. | VIVA BIOTECH (01873): INTERIM REPORT 2026 | 3 | HKEx | ||
| 26.08. | Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth | 333 | PR Newswire | Results Highlights for Interim Results ended 30 June 2026Revenue reached RMB1,006.5 million, increasing by 21.0% YoYGross profit amounted to RMB341.7 million, increasing... ► Artikel lesen | |
| 26.08. | Viva Biotech Holdings Announces Decline In H1 Profit | 1 | RTTNews | ||
| 26.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 14.08. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 2 | HKEx | ||
| 14.07. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 26.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 25.06. | VIVA BIOTECH (01873): VOLUNTARY ANNOUNCEMENT GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
| 25.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 18.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 03.06. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 27.05. | Viva Biotech: From Hit Identification to Lead Optimization: Building Scientific Continuity in Early Drug Discovery | 865 | PR Newswire | SHANGHAI, May 27, 2026 /PRNewswire/ -- On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated... ► Artikel lesen | |
| 26.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 17.03. | Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA | 786 | PR Newswire | SHANGHAI, March 17, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting... ► Artikel lesen | |
| 29.12.25 | Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities | 652 | PR Newswire | SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader... ► Artikel lesen | |
| 15.12.25 | Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. | 569 | PR Newswire | STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,411 | -1,23 % | Valneva-Aktie über der 50-Tage-Linie: Positive Shigella-Daten treiben an | ||
| NOVONESIS | 60,38 | +0,07 % | Novonesis taps China for global biosolutions | ||
| GENMAB | 464,20 | -0,04 % | Genmab A/S: Grant of Restricted Stock Units and Warrants to Employees in Genmab | ||
| ARBUTUS BIOPHARMA | 3,740 | -0,27 % | Arbutus Biopharma: FDA hebt klinischen Stopp auf - wie weit trägt die Aktie? | ||
| BEONE MEDICINES LTD ADR | 366,00 | -0,54 % | If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Today | ||
| MUSTGROW BIOLOGICS | 0,180 | -14,29 % | Aktien für gesündere Ernten - Novo Nordisk, MustGrow Biologics, Nestlé zwischen Appetit und Anbau | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Gesünder zu leben bedeutet heute auch, den eigenen Appetit ärztlich zu steuern. Wer abnimmt, isst anders und fragt genauer, woher... ► Artikel lesen | |
| VERICEL | 53,00 | -0,93 % | Vericel auf Stephens-Konferenz: Starkes Quartal und vorsichtiger Ausblick auf 2027 | ||
| SINO BIOPHARM | 0,619 | -0,88 % | CMBI Raises SBP GROUP TP to HKD9 as Multiple Innovative Drugs Included in National Medical Insurance | ||
| MOLECULIN BIOTECH | 6,173 | -13,98 % | Moleculin receives South Korean patent for Annamycin reconstitution | ||
| FAETH THERAPEUTICS | 7,950 | -4,22 % | Faeth Therapeutics: Studiendaten und Roche-Partnerschaft sorgen für vorbörslichen Kurssprung | ||
| ZAI LAB LTD ADR | 21,200 | +4,95 % | Zai Lab auf Jefferies Global Healthcare Conference: Pipeline nähert sich strategischem Wendepunkt | ||
| BIOXCEL THERAPEUTICS | 0,065 | 0,00 % | BioXcel Therapeutics, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| REGENXBIO | 6,700 | +1,09 % | Capricor, Regenxbio among gainers as White House pulls Trump's FDA pick | ||
| ZEVRA THERAPEUTICS | 8,720 | +3,07 % | Guggenheim senkt Kursziel für Zevra Therapeutics nach EU-Rückschlag | ||
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen |